Guta Tefera¹, Anbessa Bekele², Habtamu Getahun³ and Yesuneh Tefera⁴*

¹Department of Clinical Pharmacy, Guder General Hospital, Oromia, Ethiopia
²Pharmcautical Sciences, Institute of Health, School of Pharmacy, Jimma University, Ethiopia
³School of Pharmacy, Tulu Bolo General Hospital, Oromia Region, Ethiopia
⁴Msc student at Jimma, Department of Pharmaceutical chemistry, University ( pharmaceutical Quality Assurance and Regulatory Affairs), School of Pharmacy, Lecturer at University of Gondar Ethiopia

*Corresponding Author: Yesuneh Tefera, Msc student at Jimma, Department of Pharmaceutical chemistry, University ( pharmaceutical Quality Assurance and Regulatory Affairs), School of Pharmacy, Lecturer at University of Gondar Ethiopia.

Received: April 20, 2022; Published: May 30, 2022

Abstract

Substandard and falsified medicines, which are caused by low-quality drugs, pose a serious global health threat, resulting in over a million patient deaths each year, reducing the effectiveness of medical treatment, contributing to drug-resistant infections, depleting national health resources, and endangering public health in both resource-rich and resource-poor countries. Poor-quality medicines are harmful to people's health, especially when they're antimicrobials used to treat infectious diseases in high-burden communities. As multinational manufacturing and distribution systems become more complicated, the problem of inferior and fraudulent medical products continues to develop. Because of this complexity, there is a greater chance of manufacturing errors or medicines degrading between the plant and the consumer. Legislation, manufacturing procedures, supply chain management, as well as detection and reporting mechanisms are all being used to combat substandard and fraudulent pharmaceuticals. In addition to these initiatives, from a social standpoint, pharmacists' resourceful placement in all businesses, as well as public health education and involvement, should be optimized. This literature evaluation is being undertaken as a pilot study to determine the impact and insights for future research in order to better understand the impact of inferior and counterfeit medicines.

Keywords: Falsified Medicines; Substandard Medicines; Public Health

References

1. Tim K., et al. “The Global Counterfeit Drug Trade: Patient Safety and Public Health Risks”. Journal of Pharmaceutical Sciences 11 (2011): 4571-4579.
2. “A study on the public health and socioeconomic impact of substandard and falsified medical products”. Geneva: World Heal Organization (2017).
3. Newton PN., et al. “Impact of poor-quality medicines in the ‘ developing ’ world”. Trends in Pharmacology Science 3 (2010): 99-101.
4. Kaur H., et al. “Quality of Artemisinin-Based Combination Formulations for Malaria Treatment : Prevalence and Risk Factors for Poor Quality Medicines in Public Facilities and Quality of Artemisinin-Based Combination Formulations for Malaria Treatment : Prevalence and Risk”. PLoS One5 (2015): 1-13.
5. Dégardin K., et al. “Understanding and fighting the medicine counterfeit market”. Journal of Pharmaceutical and Biomedical Analysis 87 (2014): 167-175.
6. M Sonal Sekhar., et al. “Counterfeit medicines: a real threat to the society”. IJPSR7 (2011): 1645-1650.
7. Newton PN., et al. “The primacy of public health considerations in defining poor quality medicines”. PLoS Medicine12 (2011): 6-10.
8. Johnston A and Holt DW. “Substandard drugs: A potential crisis for public health”. British Journal of Clinical Pharmacology 78.2 (2014): 218-243.
9. Newton PN., et al. “Counterfeit anti-infective drugs”. Lancet Infectious Disease 6 (2006): 602-613.
10. “Growing threat from counterfeit medicines”. Bulletin of the World Health Organization 88 (2010): 247-248.
11. Attaran A., et al. “How to achieve international action on falsified and substandard medicines”. BMJ 7884 (2012): 1-6.
12. Chika A., et al. “The Menace of Fake Drugs: Consequences, Causes and Possible Solutions”. Research Journal of Medical Sciences 55 (2011): 257-261.
13. P Gupta KS and AP. “Countrfeit (fake) Druds & New Technologies To Identify It in India”. IJPSR 11 (2012): 4057-4064.
14. Buckley GJ and Gostin LO. “Countering the Problem of Falsified and Substandard Drug”s. IOM (Institute Med Natl Acad Press Copyr. (2013): 624-6242.
15. Dondorp AM., et al. “Fake antimalarials in Southeast Asia are a major impediment to malaria control : multinational cross-sectional survey on the prevalence of fake antimalarials”. Tropical Medicine and International Health 12 (2004): 1241-1246.
16. Christian L., et al. “The Problem of Substandard Medicines in Developing Countries”. Work International Public Affair 81 (2012).
17. Clift C. “Counterfeit medicines : Health And Harm”. World Today Royal Inst Int Aff.12 (2012): 11-13.
18. Lubell Y., et al. “Artemisinin resistance - modelling the potential human and economic costs Artemisinin resistance - modelling the potential human and economic costs”. Malaria Journal (2014): 1-9.
19. Ghanem N. “Substandard and falsified medicines : global and local efforts to address a growing problem Key points”. Pharma Journal (2019): 1-12.
20. Suleman S., et al. “Quality of Medicines Commonly Used in the Treatment of Soil Transmitted Helminths and Giardia in Ethiopia : A Nationwide Survey”. PLOS Neglected Tropical Diseases 12 (2014): 1-16.
21. Nsimba SED. “Problems Associated With Substandard and Counterfeit Drugs In Developing Countries: A Review Article on Global Implications of Counterfeit Drugs in the Era of Anti-Retroviral (ARVS) Drugs In free Market Economy”. East African Journal of Public Health3 (2008): 205-210.
22. Bloom G., et al. “Markets, information asymmetry and health care : Towards new social contracts”. Social Science and Medicine 66 (2011): 2076-2087.
23. Kanavos P., et al. “Options for nancing and optimizing medicines in resource-poor countries”. World Health Report Background (2010).
24. Wertheimer AI., et al. “Safeguarding against substandard/counterfeit drugs: Mitigating a macroeconomic pandemic”. Research in Social and Administrative Pharmacy 1 (2009): 4-16.
25. Substandard/Spurious/Falsely-Labelled/Falsified/Counterfeit Medical Products Report by the Director-General 63 (2011).
26. “Eye on the Ball: Medicine regulation - not IP enforcement - can best deliver quality medicine” (2011).
27. “WHO’s role in the prevention and control of medical products of compromised quality, safety and efficacy such as substandard/spurious/falsely- labelled/falsified/counterfeit medical products”. 63 (2011): 1-7.
28. WHO member state mechanism on substandard/spurious/falsely- labelled/falsified/counterfeit (ssffc) medical products working definitions (2015): 33-36.
29. “WHO Global Surveillance and Monitoring System for substandard and falsified medical products”. Geneva: Geneva World Heal Organ (2017).
30. Cockburn R., et al. “The Global Threat of Counterfeit Drugs : Why Industry and Governments Must Communicate the Dangers”. PLoS Medicine4 (2005): 302-308.
31. Swaminath G. “Faking it - II : Countering and preventing counterfeiting of drugs”. Indian Journal of Psychiatry1 (2020): 9-11.
32. Commission E. “Report on the EU Customs Enforcement of Intellectual Property Rights: Result EU Bord”. (2011).
33. Reynolds L and Mckee M. “Organised crime and the efforts to combat it : a concern for public health”. Global Health21 (2010): 15-17.
34. Erhun WO., et al. “Drug Regulation and Control in Nigeria : The Challenge of Counterfeit Drugs”. Journal of Health and Population in Developing Countries2 (2001): 23-34.
35. Pollack A. “Medicare coverage for breast cancer drug ends in some states”. New York Times Prescr Blog1 (2011): 1-23.
36. Dusetzina BSB., et al. “How Do Payers Respond to Regulatory Actions ? The Case of Bevacizumab”. Journal of Oncology Practice4 (2015): 313-318.
37. Lamy M and Liverani M. “Tackling Substandard and Falsified Medicines in the Mekong : National Responses and Regional Prospects”. Asia Pacific Policy Studies2 (2015): 245-254.
38. Liang BA. “Fade to black:Importation and counterfeit drugs”. American Journal of Law and Medicine (2006).
39. Kaplan WA., et al. “Policies to promote use of generic medicines in low and middle income countries : A review of published literature, 2000 – 2010”. Health Policy (New York)3 (2012): 211-224.
40. Mackey TK and Liang BA. “Pharmaceutical digital marketing and governance: Illicit actors and challenges to global patient safety and public health”. Global Health (2013).
41. Frontini R. “Falsified Medicines Directive: are we heading in the”. Journal of Medicine Access1 (2017): 55-57.
42. Isles M. “What’s in a word? Falsified/counterfeit/fake medicines - the definitions debate”. Journal of Medicine Access 1 (2017): 40-48.
43. “Combatting Substandard and Falsified Medicines”. USP Global Public Policy Position (2020): 1-6.
44. Mhando L., et al. “Public Awareness and Identification of Counterfeit Drugs in Tanzania : A View on Antimalarial Drugs”. Advances in Public Health 2016 (2016): 18-23.
45. Hoen E and Pascual F. “Counterfeit medicines and substandard medicines : Different problems requiring different solutions”. Author (s): Ellen ’ t Hoen and Fernando Pascual Source : Journal of Public Health Policy 36.4 (2015): 384-389.
46. Sankalp Yadav GR. “Counterfeit drugs: Problem of developing and developed countries [6]”. International Journal of Pharmaceutical Chemistry and Analysis 1 (2015): 46-50.

Citation

Citation: Yesuneh Tefera., et al. “Impact of Substandard and Falsified Medicines on Public Health: A Review". Acta Scientific Pharmaceutical Sciences 6.6 (2022): 33-46.

Copyright

Copyright: © 2022 Yesuneh Tefera., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.